Expanding Probiotic Possibilities with OPTI-BIOME®

 

IPA Booth- AA122

This year at SupplySide West 2017, BIO-CAT Microbials Chris Penet and Marc Jensen will present at the Probiotics Resource Center organized by the International Probiotics Association (IPA).

We will discuss the following on Wednesday, September 27 at 4:20 pm:

Naturally stable probiotic strains are the answer for companies hoping to capture a share of the rapidly expanding probiotic market, but shelf-stable strains with proven benefits are essential. Learn about updated research on OPTI-BIOME® Bacillus subtilis MB40 and other strains in BIO-CAT Microbial’s portfolio, and get insight into the latest food applications opportunities.

For more information see Probiotics Resource Center.

BIO-CAT Speaking at Probiotic Marketplace

Ingredient Marketplace logo large copy BIO-CAT’s Vice-President, Chris Penet and BIO-CAT Microbials Technical Director, Dr. Steve Lamb will present at Probiotic Marketplace, the day-and-a-half event that kicks off the Ingredient Marketplace trade show. Penet and Dr. Lamb will discuss the “Use of Bacillus Probiotics to Promote Health and Well-being”.

The world of probiotics and available information is changing daily.  How do manufacturers, formulators and consumers keep up with the volume of data and rapidly changing information?  How do they know what is scientifically valid, appropriate to rely on and is safe?  Add to that keeping up with, understanding and interpreting the emerging rules from a regulatory perspective and the landscape of information and data can be overwhelming.  From the point of the consumer, one can only wonder how they can make informed decisions.  It wasn’t all that long ago that the word “bacteria” was an omen of danger, illness, or worse.  Bacteria associated with food borne illness, MRSA, C. diff, cholera and so on, was all the consumer heard from news sources.  Those “bad” bacteria still exist but now after the last 25 years or so, the concept of “good” bacteria has entered the consumer’s vocabulary. Their discussions over coffee and in grocery store aisles are about trying to determine how best to introduce these “good bacteria” to their families and their daily regimen.

That dialogue started when consumers began to learn that the yogurt or cheese they had been consuming was actually beneficial in many ways related to their overall health.  They then began to learn and understand that they could introduce even more of these good bacteria by purchasing highly concentrated forms of them in capsules.  Media outlets began touting their benefits and initial studies began to emerge that these good bacteria might actually impact their overall health and immunity.

The flow of information continues, data is constantly being developed and possibilities touted.  However, the consumer now has to also contend with other questions- does my capsule actually contain the levels stated? Is a one strain better than 2?  2 better than 4? What strain produces benefits for my IBS? My immunity from flu? Inflammation? It is becoming increasingly obvious that many types of probiotics can address many of the issues and research must continue to develop more and more information.  The science addressing these questions must be done and validated and clinical trials need to address specific issues and follow the protocols that can result in clearly defined results.  The research into new strains and which strains can contribute to the diversity needed to address the various ailments must continue as well.

The class of bacteria known as Bacillus offers new unique beneficial bacteria that not only can be synergistic with the current strains of Lactobacillus and Bifidobacteria, but also has unique, natural stability and an amazing range of metabolites (including enzymes) that they can produce.  These properties make Bacillus a valuable addition to the toolbox of probiotics that can potentially address many health issues. One particular  strain of Bacillus subtilis, Bacillus subtilis MB40 is a new strain that has been shown in clinical trials to improve digestive health and one that holds great promise  also in other areas such as potential heart health improvements and pathogen reduction through competitive inhibition.

MB40 has been successfully tested in two large clinical trials for safety, digestive health and improvement in overall wellbeing.  The results of these trials will be discussed in detail but include the following data and conclusions:

-In a trial of 29 individuals, no adverse effects were reported after 30 days of consuming MB40; patients reported over 70 initial digestive  ailments when starting the trial that were reduced to less than 20 by the end of the 30 days.

-in 21 of the 29 individuals, decreases in serum triglycerides from initial readings to conclusion of the trial were measured.  Thus, indicating the potential for MB40 to aid in improving key factors in cardiac health

-in this trial glucose levels were unchanged in any of the patients indicating the potential for MB40 to aid in controlled breakdown of carbohydrates and alleviating spikes in blood glucose levels

-MB40 has been shown to produce a wide variety of enzymes in vitro.  The scope of enzymes produced may indicate the ability for MB40 to aid in digestion for patients sensitive to certain food groups such as specific proteins or carbohydrates.

The data from this trial is currently in process to be published in a peer reviewed journal.

A second, larger clinical trial (100 individuals in a double-blind study) has assessed bloating as a primary end point coupled with 9 secondary outcomes.  This trial is scheduled to be concluded in Spring 2017 but as of this writing no adverse effects were reported, all patients who have completed the trial reported significant decreases in bloating and overall improvement in digestive health and decreases in symptoms.

Future research will also focus on what happens if world class probiotics and world class enzymes can be combined into truly functional foods?  Imagine combining the best long distance runners (probiotics) which can compete with bad bacteria, produce metabolites that enhance health with the best sprinters (enzymes) that work to break down organic materials immediately in the stomach and digestive tract to provide not only nutrition to the body but also food to the probiotic to enhance their growth and overall ability to contribute benefits faster.  Imagine a probiotic that can modulate triglycerides combined with a lipase enzyme that breaks down dietary triglycerides so effectively that the triglyceride cannot be reformed in the blood system?  These realities are being researched today and will become part of the dialogue as to how health can be enhanced with probiotics even farther in the future.

Bacillus probiotics are proven safe, offer health benefits, can be combined with other ground breaking technologies and offer the ability to develop unique ways to deliver the benefits of probiotics through common food products.